Mesalazine, tripterygium glycosides    (DrugBank: Mesalazine, Tripterygium)

1 disease
IDDisease name (Link within this page)Number of trials
96Crohn disease1

96. Crohn disease    [ 2,209 clinical trials,   1,276 drugs,   (DrugBank: 240 drugs),   166 drug target genes,   210 drug target pathways]
Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 2,209 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02044952
(ClinicalTrials.gov)
January 201419/1/2014Efficacy and Safety Study of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction RemissionProspective Experimental of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction RemissionInflammatory Bowel Diseases;Crohn's Disease;Gastrointestinal Diseases;Digestive System Diseases;Intestinal DiseasesDrug: Mesalazine, Tripterygium glycosidesZhu WeimingNULLRecruiting18 Years75 YearsBoth40Phase 2;Phase 3China